FDA Accepts New Refractory Mantle Cell Lymphoma Treatment

Refractory mantel cell lymphoma (MCL) in people who have had at least two rounds of systemic treatment, involving a Bruton tyrosine kinase, can now be treated with lisocabtagene maraleucel, based on a statement from the FDA.

CEO of the Lymphoma Research Foundation explained in a news release “The approval of [Liso-cel] brings a new CAR T cell therapy option to patients battling relapsed or refractory MCL,”

They continued to say “Each advance in treatment represents important progress in improving outcomes for patients, and this news builds upon this progress with a new potentially transformative treatment where there are currently limited options.”